View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Alvaro del Pozo
  • Alvaro del Pozo

SAFRAN: RDOS. 2025 (ANÁLISIS BANCO SABADELL)

Rdos. 2025 vs 2024: Ventas: 31.329 M euros (+14,7% vs +14,2% BS(e) y +15,3% consenso); EBIT: 5.196 M euros (+26,1% vs +26,0% BS(e) y +26,7% consenso); BDI: 3.174 M euros (+3,5% vs +12,3% BS(e) y +12,9% consenso).

Olfa Taamallah ... (+2)
  • Olfa Taamallah
  • Yan Derocles
Olfa Taamallah ... (+2)
  • Olfa Taamallah
  • Yan Derocles
Research Department
  • Research Department

INFORME DIARIO 13 FEBRERO + RDOS. ESPAÑA. IDEAS DESTACADAS Y PREVIEWS ...

COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: REPSOL, TELEFÓNICA. EUROPA: HERMÈS INT., L’ORÉAL, SAFRAN. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 4T’25 que se publicarán en España y Europa en los próximos días. Siguen las dudas sobre la rentabilidad de la IA Las bolsas europeas revertieron las ganancias en el tramo final de la sesión, presionadas...

Vivendi: 1 director

A director at Vivendi sold 345,517 shares at 2.290EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...

Novartis AG: 1 director

A director at Novartis AG sold 7,500 shares at 156.208USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

 PRESS RELEASE

Novartis breaks ground on new global Biomedical Research center in San...

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel, SwitzerlandApproximately 466,000-square-foot site with AI-enabled discovery capabilities, expected to house about 1,000 employees Part of a USD 23 billion US investment to expand R&D and advanced manufacturing to reach more patients East Hanover, February 6, 2026 – Novartis today broke ground on a new, s...

Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures
Martijn Den Drijver
  • Martijn Den Drijver
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Aalberts: Preview: Another quarter in no man's land? / Ahold Delhaize: Confirms the acquisition of Delfood / AGEAS: China – state to inject capital into insurers / AkzoNobel: Tepid 4Q25 results and FY26 outlook / D'Ieteren: Belgian car registrations down 19%, 65% of 2019 level, VW down only 5% / Xior Student Housing: Sound organic trends continue, two-year guidance revealed

David Vagman ... (+16)
  • David Vagman
  • CFA
  • Dirk Verbiesen
  • Francesca Ferragina
  • Jason Kalamboussis
  • Marc Hesselink
  • CFA
  • Marc Zwartsenburg
  • CEFA
  • Maxime Stranart
  • Michiel Vereycken
  • Quirijn Mulder
  • Reg Watson
  • CFA
  • Thymen Rundberg
  • Tijs Hollestelle

ING Benelux Favourites/Aedifica, Ageas, ASM International, Basic-Fit, ...

We refresh our ING Benelux Favourites list. We apply a fundamental bottom up approach in which we select stocks which provide the best upside within our Benelux coverage universe and these stocks need clear catalysts. Additions/deletions: We add the following names to the ING Benelux Favourites list: Ageas: Ageas has done multiple deals; its most recent purchase of the 25% stake BNP Paribas had in its Belgian ops, is an accretive deal and we believe makes the Belgian operations ready for a pot...

Jason Kalamboussis
  • Jason Kalamboussis

Ageas/Shaking shackles, coming together/BUY

Moving away from dependence on Asian earnings (now c.30%), while carefully managing its M&A path, we believe AGEAS is well positioned to see an earnings acceleration in the coming years. China upstreams are coming through, while the share price of its Chinese partner CTIH has doubled in 12 months. BNP PARIBAS has increased its stake in the Group (from c.15% to c.23%) at the same time moving out of the Belgian entity AG, and the Belgian government is looking at options to increase its 6.3% stake....

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch